Medical Research and Clinical Trials

Salk Institute Breakthrough: Estrogen-Related Receptors Identified as Key to Unlocking Cellular Energy and Combating Muscle Fatigue

• Medical Research and Clinical Trials

Salk Institute Breakthrough: Estrogen-Related Receptors Identified as Key to Unlocking Cellular Energy and Combating Muscle Fatigue

Asro June 17, 2026

LA JOLLA, CA – May 12, 2025 – In a discovery poised to revolutionize the treatment of...

Read More Read more about Salk Institute Breakthrough: Estrogen-Related Receptors Identified as Key to Unlocking Cellular Energy and Combating Muscle Fatigue

Cambridge Breakthrough Achieves Unprecedented 100% Survival Rate in Aggressive Inherited Breast Cancers

• Medical Research and Clinical Trials

Cambridge Breakthrough Achieves Unprecedented 100% Survival Rate in Aggressive Inherited Breast Cancers

Rifan Muazin June 17, 2026

Cambridge, UK – In a monumental stride for oncology, researchers at Cambridge have unveiled a groundbreaking treatment...

Read More Read more about Cambridge Breakthrough Achieves Unprecedented 100% Survival Rate in Aggressive Inherited Breast Cancers

Revolutionising Brain Tumour Diagnosis: Nottingham Breakthrough Cuts Weeks of Agony to Mere Hours

• Medical Research and Clinical Trials

Revolutionising Brain Tumour Diagnosis: Nottingham Breakthrough Cuts Weeks of Agony to Mere Hours

Nila Kartika Wati June 16, 2026

Nottingham, UK – A monumental leap in medical diagnostics has emerged from the collaborative efforts of scientists...

Read More Read more about Revolutionising Brain Tumour Diagnosis: Nottingham Breakthrough Cuts Weeks of Agony to Mere Hours

EHA 2026: Promising New Avenues Emerge for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatment

• Medical Research and Clinical Trials

EHA 2026: Promising New Avenues Emerge for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatment

Nila Kartika Wati June 16, 2026

GENEVA, SWITZERLAND – [Date of Publication] – The European Hematology Association (EHA) 2026 Congress has become a...

Read More Read more about EHA 2026: Promising New Avenues Emerge for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatment

Unraveling the Silent Risk: Genetics and Treatment Shape Secondary Cancer Threat for Childhood Cancer Survivors

• Medical Research and Clinical Trials

Unraveling the Silent Risk: Genetics and Treatment Shape Secondary Cancer Threat for Childhood Cancer Survivors

Lina Hope June 16, 2026

FOR IMMEDIATE RELEASE ST. JUDE CHILDREN’S RESEARCH HOSPITAL, MEMPHIS, TN – A groundbreaking study published today in...

Read More Read more about Unraveling the Silent Risk: Genetics and Treatment Shape Secondary Cancer Threat for Childhood Cancer Survivors

AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026

• Medical Research and Clinical Trials

AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026

Ali Ikhwan June 16, 2026

Geneva, Switzerland – June 13, 2026 – AvenCell Therapeutics has presented updated clinical results for its investigational...

Read More Read more about AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026

Navigating the Complex Landscape: Why Strategic CDMO Partnerships are Paramount for Biopharma Success

• Medical Research and Clinical Trials

Navigating the Complex Landscape: Why Strategic CDMO Partnerships are Paramount for Biopharma Success

Basiran June 16, 2026

In the rapidly evolving biopharmaceutical industry, the path from scientific breakthrough to patient access is fraught with...

Read More Read more about Navigating the Complex Landscape: Why Strategic CDMO Partnerships are Paramount for Biopharma Success

GLP-1 Receptor Agonists Show Promising Oncology Potential Beyond Metabolic Disease, ASCO 2026 Reveals

• Medical Research and Clinical Trials

GLP-1 Receptor Agonists Show Promising Oncology Potential Beyond Metabolic Disease, ASCO 2026 Reveals

Siti Muinah June 16, 2026

Chicago, IL – June 20, 2026 – The groundbreaking potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs), long...

Read More Read more about GLP-1 Receptor Agonists Show Promising Oncology Potential Beyond Metabolic Disease, ASCO 2026 Reveals

Groundbreaking Triple Therapy from Keck Medicine Unlocks New Hope for Glioblastoma Patients, Potentially Extending Survival

• Medical Research and Clinical Trials

Groundbreaking Triple Therapy from Keck Medicine Unlocks New Hope for Glioblastoma Patients, Potentially Extending Survival

Azzam Bilal Chamdy June 15, 2026

LOS ANGELES, CA – [Date of Publication] – A new beacon of hope has emerged for patients...

Read More Read more about Groundbreaking Triple Therapy from Keck Medicine Unlocks New Hope for Glioblastoma Patients, Potentially Extending Survival

Lilly’s Novel JAK2 Inhibitor Shows Promising Early Results in Myelofibrosis, Offering New Hope for Patients

• Medical Research and Clinical Trials

Lilly’s Novel JAK2 Inhibitor Shows Promising Early Results in Myelofibrosis, Offering New Hope for Patients

Ammar Sabilarrohman June 15, 2026

Indianapolis, IN – June 15, 2026 – Eli Lilly and Company has unveiled encouraging Phase I data...

Read More Read more about Lilly’s Novel JAK2 Inhibitor Shows Promising Early Results in Myelofibrosis, Offering New Hope for Patients